Minimal Residual Disease Testing - Medicare Advantage

Minimal Residual Disease (MRD) molecular diagnostic testing for cancer — including MolDX-listed assays and MRD testing for solid tumors and Non‑Muscle Invasive Bladder Cancer (NMIBC) risk stratification — is covered for Medicare Advantage members. Coverage is governed by the applicable CMS NCD/LCD/LCA and MolDX requirements, is limited to each Medicare Administrative Contractor's (MAC) geographic jurisdiction, and is subject to the specific indications, frequency, and test-specific criteria detailed in the referenced LCDs/LCAs (e.g., L38835, L35000, NCD 90.2).

"Intermediate Risk: Recurrence within 1 year"

Sign up to see full coverage criteria, indications, and limitations.